Showing results (181-190 of 262) with videos related to
Sort By:
Pageof 27
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2008
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720Maria R Baer, Stephen L George, Michael A Caligiuri, et al.Leukemia & Lymphoma|July 19, 2013
Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studiesDaphne R Friedman, Mark C Lanasa, Patricia H Davis, et al.The Journal of Trauma|May 12, 2009
Management of patients with anterior abdominal stab wounds: a Western Trauma Association multicenter trialWalter L Biffl, Krista L Kaups, C Clay Cothren, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 5, 2005
Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphomaMyron S Czuczman, Aron Thall, Thomas E Witzig, et al.Leukemia|September 12, 2008
Apolipoprotein E genotype as a determinant of survival in chronic lymphocytic leukemiaJ B Weinberg, A D Volkheimer, M Mihovilovic, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2003
Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemiaDavid A Rizzieri, Valerie K Ibom, Joseph O Moore, et al.Clinical Lymphoma, Myeloma & Leukemia|December 16, 2010
A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapseAnjali S Advani, Mazyar Shadman, Francis Ali-Osman, et al.Journal of Vascular Surgery Cases and Innovative Techniques|December 26, 2022
Deriving International Classification of Diseases, 9th and 10th revision, codes for identifying and following up patients with diabetic lower extremity ulcersXavier P Fowler, Mark A Eid, J Aaron Barnes, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2009
A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemiaDaphne R Friedman, J Brice Weinberg, William T Barry, et al.Leukemia & Lymphoma|August 11, 2011
Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemiaMark C Lanasa, Patricia H Davis, Michael Datto, et al.Pageof 27